Credit Suisse analyst Dan Leonard raised the firm’s price target on Exact Sciences to $90 from $75 following quarterly results. The firm keeps a Neutral rating on the shares given that the durable value of its Cologuard test is realized while its pipeline could translate to sales more slowly than investors appreciate.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EXAS: